Marc Carrier: Proud to Share the Results of the WAVe Study
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on LinkedIn:
”Proud to share the results of the WAVe Study published in AjHematology
In this Canadian multicenter collaboration across six academic centers, we evaluated weight-adjusted dalteparin dosing (up to 33,000 IU/day) in patients with cancer-associated thrombosis weighing >90 kg.
Despite early study termination due to recruitment challenges — following the rapid uptake of DOACs for VTE and updated ISTH guidance removing the upper weight limit for DOAC use — our findings remain clinically relevant:
- Major bleeding: 5.3% at 30 days
- Recurrent VTE: 1.2% at 30 days
- No significant drug accumulation (based on anti-Xa levels)
These results suggest that weight-adjusted LMWH remains a safe and effective option for selected patients with cancer and obesity, particularly those at higher bleeding risk or with contraindications to DOACs.”
Read the full article here.
Article: A Multicenter Prospective Cohort Study on the Use of Weight-Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism—The WAVe Study
Authors: Tzu-Fei Wang, Erik Yeo, Peter L. Gross, Chantal Séguin, Cynthia Wu, Sudeep Shivakumar, Ranjeeta Mallick, Aurélien Delluc, Julien D’Astous, Miriam Kimpton, Guillaume Roberge, Deborah M. Siegal, Tobias Tritschler, Grégoire Le Gal, Marc Carrier
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 16, 2026, 06:05Wolfgang Miesbach on Jacob Lund’s Study: How to Define FVIII Bioequivalence
-
Jan 16, 2026, 05:52Piotr Czempik Shares His Latest Contribution to Acta Haematologica Polonic
-
Jan 16, 2026, 05:44Florian Piekarski on Perioperative Blood Management When Allogeneic Transfusion is Not Aaccepted
-
Jan 16, 2026, 05:00Plaque Rupture and Thrombosis
-
Jan 16, 2026, 04:52Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor
-
Jan 16, 2026, 04:51Higher-Dose Clotting Factor Prophylaxis Does Not Reduce Postpartum Hemorrhage in Women with von Willebrand Disease
-
Jan 16, 2026, 04:48Reza Shojaei on Plasma Donation as Life-Changing Medicine in Motion
-
Jan 16, 2026, 04:11Open-Label Extension Study of Marstacimab: Pfizer Has Reported a Fatal Event
-
Jan 16, 2026, 04:11Why is DVT More Common In the Left Leg? Dr Raheel Moazzam’s New Study Gives Answers!